866-997-4948(US-Canada Toll Free)

Hepatocellular Carcinoma Pipeline Review, H2 2012

Published By :

Global Markets Direct

Published Date : Nov 2012

Category :

Oncology

No. of Pages : 566 Pages


Global Markets Directs, \'Hepatocellular Carcinoma Pipeline Review, H2 2012\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Hepatocellular Carcinoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hepatocellular Carcinoma. 

Hepatocellular Carcinoma Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Hepatocellular Carcinoma.
  • A review of the Hepatocellular Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Hepatocellular Carcinoma pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Hepatocellular Carcinoma.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Hepatocellular Carcinoma pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 9
List of Figures 12
Introduction 14
Global Markets Direct Report Coverage 14
Hepatocellular Carcinoma Overview 15
Therapeutics Development 16
An Overview of Pipeline Products for Hepatocellular Carcinoma 16
Hepatocellular Carcinoma Therapeutics under Development by Companies 18
Hepatocellular Carcinoma Therapeutics under Investigation by Universities/Institutes 25
Late Stage Products 33
Comparative Analysis 33
Mid Clinical Stage Products 34
Comparative Analysis 34
Early Clinical Stage Products 35
Comparative Analysis 35
Discovery and Pre-Clinical Stage Products 36
Comparative Analysis 36
Hepatocellular Carcinoma Therapeutics Products under Development by Companies 37
Hepatocellular Carcinoma Therapeutics Products under Investigation by Universities/Institutes 43
Companies Involved in Hepatocellular Carcinoma Therapeutics Development 53
Bristol-Myers Squibb Company 53
Biocompatibles International plc 54
Boehringer Ingelheim GmbH 55
Celsion Corporation 56
Abbott Laboratories 57
Biogen Idec Inc. 58
Amgen Inc. 59
AstraZeneca PLC 60
Eli Lilly and Company 61
GlaxoSmithKline plc 62
Tekmira Pharmaceuticals Corp. 63
Daiichi Sankyo Company, Ltd 64
Gamida Cell Ltd. 65
Light Sciences Oncology, Inc. 66
ZIOPHARM Oncology, Inc. 67
Novartis AG 68
ImClone Systems Incorporated 69
Eisai Co., Ltd. 70
MDRNA, Inc. 71
Ono Pharmaceutical Co., Ltd. 72
Pfizer Inc. 73
Galaxy Biotech, LLC 118
Therapure Biopharma Inc. 119
VectorLogics, Inc. 120
Polaris Group 121
Gradalis Inc. 122
Hepatocellular Carcinoma Therapeutics Assessment 123
Assessment by Monotherapy Products 123
Assessment by Combination Products 124
Assessment by Route of Administration 125
Assessment by Molecule Type 128
Drug Profiles 131
tigatuzumab - Drug Profile 131
lenvatinib - Drug Profile 132
brivanib alaninate - Drug Profile 134
brivanib alaninate - Drug Profile 136
regorafenib - Drug Profile 138
sorafenib tosylate - Drug Profile 140
axitinib - Drug Profile 142
cixutumumab - Drug Profile 144
vandetanib - Drug Profile 145
linifanib - Drug Profile 147
MB-07133 - Drug Profile 149
foretinib - Drug Profile 151
Im-01 - Drug Profile 153
doxorubicin - Drug Profile 154
ALN-VSP - Drug Profile 156
belinostat - Drug Profile 157
everolimus - Drug Profile 160
ramucirumab - Drug Profile 163
cabozantinib - Drug Profile 165
Vector gutless IL12 - Drug Profile 167
JX-594 - Drug Profile 168
Vector Semliky IL12 - Drug Profile 170
resminostat - Drug Profile 171
doxorubicin - Drug Profile 174
PI-88 - Drug Profile 176
HepTide - Drug Profile 178
mepacrine - Drug Profile 179
Provecta - Drug Profile 182
NV-128 - Drug Profile 184
darinaparsin - Drug Profile 186
orantinib - Drug Profile 188
YN-968D1 - Drug Profile 189
nintedanib - Drug Profile 191
sorafenib tosylate - Drug Profile 369
Sorafenib Tosylate + Temsirolimus - Drug Profile 370
Cisplatin - Drug Profile 371
Gemcitabine + Oxaliplatin + Nexavar - Drug Profile 372
Bevacizumab + Sirolimus - Drug Profile 374
doxorubicin - Drug Profile 376
celecoxib + epirubicin hydrochloride - Drug Profile 377
Sorafenib + Cisplatin + Fluorouracil - Drug Profile 378
Cisplatin + Doxorubicin + Mitomycin C - Drug Profile 380
Everolimus + Bevacizumab - Drug Profile 382
cixutumumab - Drug Profile 383
Doxorubicin + Sorafenib - Drug Profile 385
Sorafenib + Gemcitabine + Cisplatin - Drug Profile 386
TACE + Nexavar - Drug Profile 388
YN-968D1 - Drug Profile 389
let-7 - Drug Profile 390
Theracim + TACE - Drug Profile 392
Selumetinib - Drug Profile 393
MK-2206 - Drug Profile 394
MCT-485 - Drug Profile 395
Bavituximab + Sorafenib - Drug Profile 396
LY-2157299 - Drug Profile 397
temsirolimus - Drug Profile 398
PX-228 - Drug Profile 399
DC-101 + Sorafenib - Drug Profile 400
brivanib alaninate - Drug Profile 401
Bevacizumab + Erlotinib - Drug Profile 402
TACE + Hepasphere - Drug Profile 404
Bevacizumab + TACE - Drug Profile 405
Sorafenib + Zoledronic Acid - Drug Profile 406
AFP-Based Vaccines - Drug Profile 407
5-Fluorouracil + Sorafenib - Drug Profile 408
sorafenib tosylate - Drug Profile 409
etodolac + propranolol + sorafenib - Drug Profile 410
Sunitinib + Chemoembolization - Drug Profile 411
E7050 + Sorafenib - Drug Profile 412
axitinib - Drug Profile 414
axitinib - Drug Profile 415
tegafur - Drug Profile 416
DasKloster-001401 - Drug Profile 417
TRC 105 + Sorafenib - Drug Profile 418
Doxorubicin Eluting Beads + Sorafenib - Drug Profile 419
Temsirolimus + Sorafenib - Drug Profile 420
Recombinant Adenovirus p53 + 5-Fluorouracil - Drug Profile 421
Revlimid + Nexavar - Drug Profile 422
sorafenib tosylate - Drug Profile 423
Sorafenib + Pravastatin - Drug Profile 424
NK Cell Product - Drug Profile 426
TBI-302 - Drug Profile 428
Anti miRNA-21 - Drug Profile 429
Interferon Alfa - Drug Profile 430
xylocydine - Drug Profile 431
sirolimus - Drug Profile 432
TRC-105 + Nexavar - Drug Profile 433
ColoAd-1 - Drug Profile 434
Capecitabine + Peginterferon Alfa-2a - Drug Profile 435
VLI-03B - Drug Profile 436
Sorafenib + Pravastatin - Drug Profile 437
Nemorubicin + Cisplatin - Drug Profile 438
TACE + Miriplatin - Drug Profile 439
sorafenib tosylate - Drug Profile 440
ALF-2111 - Drug Profile 441
H-102 - Drug Profile 442
ADV-TK + Ganciclovir - Drug Profile 443
Modified DC Vaccine - Drug Profile 444
Sorafenib + Miriplatin - Drug Profile 445
PKI-587 + Sorafenib - Drug Profile 446
TACE + Miriplatin - Drug Profile 447
PI-103 + Sorafenib - Drug Profile 448
GAL-F2 Against Fibroblast Growth Factor 2 - Drug Profile 449
NGR-008 - Drug Profile 450
Hepatocellular Carcinoma Therapeutics Drug Profile Updates 451
Hepatocellular Carcinoma Therapeutics Discontinued Products 530
Hepatocellular Carcinoma Therapeutics - Dormant Products 532
Hepatocellular Carcinoma Product Development Milestones 541
Featured News & Press Releases 541

Appendix 549
Methodology 549
Coverage 549
Secondary Research 549
Primary Research 549
Expert Panel Validation 549
Contact Us 550
Disclaimer 550

List of Table


Number of Products Under Development for Hepatocellular Carcinoma, H2 2012 32
Products under Development for Hepatocellular Carcinoma Comparative Analysis, H2 2012 33
Number of Products under Development by Companies, H2 2012 35
Number of Products under Development by Companies, H2 2012 (Contd..1) 36
Number of Products under Development by Companies, H2 2012 (Contd..2) 37
Number of Products under Development by Companies, H2 2012 (Contd..3) 38
Number of Products under Development by Companies, H2 2012 (Contd..4) 39
Number of Products under Development by Companies, H2 2012 (Contd..5) 40
Number of Products under Investigation by Universities/Institutes, H2 2012 42
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 43
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 44
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 45
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 46
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 47
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..6) 48
Comparative Analysis by Late Stage Development, H2 2012 49
Comparative Analysis by Mid Clinical Stage Development, H2 2012 50
Comparative Analysis by Early Clinical Stage Development, H2 2012 51
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 52
Products under Development by Companies, H2 2012 53
Products under Development by Companies, H2 2012 (Contd..1) 54
Products under Development by Companies, H2 2012 (Contd..2) 55
Products under Development by Companies, H2 2012 (Contd..3) 56
Products under Development by Companies, H2 2012 (Contd..4) 57
Products under Development by Companies, H2 2012 (Contd..5) 58
Products under Investigation by Universities/Institutes, H2 2012 59
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 60
Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 61
Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 62
Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 63
Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 64
Products under Investigation by Universities/Institutes, H2 2012 (Contd..6) 65
Products under Investigation by Universities/Institutes, H2 2012 (Contd..7) 66
Products under Investigation by Universities/Institutes, H2 2012 (Contd..8) 67
Products under Investigation by Universities/Institutes, H2 2012 (Contd..9) 68
Bristol-Myers Squibb Company, H2 2012 69
Biocompatibles International plc, H2 2012 70
Boehringer Ingelheim GmbH, H2 2012 71
Celsion Corporation, H2 2012 72
Abbott Laboratories, H2 2012 73
Biogen Idec Inc., H2 2012 74
Amgen Inc., H2 2012 75
AstraZeneca PLC, H2 2012 76
Eli Lilly and Company, H2 2012 77
GlaxoSmithKline plc, H2 2012 78
Tekmira Pharmaceuticals Corp., H2 2012 79
Daiichi Sankyo Company, Ltd, H2 2012 80
Gamida Cell Ltd., H2 2012 81
Light Sciences Oncology, Inc., H2 2012 82
ZIOPHARM Oncology, Inc., H2 2012 83
Novartis AG, H2 2012 84
ImClone Systems Incorporated, H2 2012 85
Eisai Co., Ltd., H2 2012 86
MDRNA, Inc., H2 2012 87
Ono Pharmaceutical Co., Ltd., H2 2012 88
Pfizer Inc., H2 2012 89
Taiho Pharmaceutical Co., Ltd., H2 2012 90
Exelixis, Inc., H2 2012 91
Bayer AG, H2 2012 92
4SC AG, H2 2012 93
IMMUNOMEDICS, INC, H2 2012 94
Can-Fite BioPharma Ltd., H2 2012 95
Ligand Pharmaceuticals Incorporated, H2 2012 96
MultiCell Technologies, Inc., H2 2012 97
NexMed, Inc., H2 2012 98
Novogen Limited, H2 2012 99
Cleveland BioLabs, Inc., H2 2012 100
Peregrine Pharmaceuticals, Inc., H2 2012 101
ARQULE, INC, H2 2012 102
Alnylam Pharmaceuticals, Inc, H2 2012 103
BTG International Ltd, H2 2012 104
TopoTarget A/S, H2 2012 105
Progen Pharmaceuticals Limited, H2 2012 106
Innocell Corporation, H2 2012 107
Jiangsu Hengrui Medicine Co., Ltd., H2 2012 108
Threshold Pharmaceuticals, Inc., H2 2012 109
Provectus Pharmaceuticals, Inc., H2 2012 110
BioAlliance Pharma SA, H2 2012 111
Simcere Pharmaceutical Group, H2 2012 112
Raptor Pharmaceuticals Corp., H2 2012 113
Sunway Biotech Co.,Ltd, H2 2012 114
Digna Biotech, S.L., H2 2012 115
Nerviano Medical Sciences S.r.l., H2 2012 116
Aegera Therapeutics Inc., H2 2012 117
Provecs Medical GmbH, H2 2012 118
GenSpera, Inc., H2 2012 119
TMRC Co., Ltd., H2 2012 120
Mondobiotech Holding AG, H2 2012 121
Celecure AS, H2 2012 122
Jennerex Biotherapeutics, Inc., H2 2012 123
Advenchen Laboratories, LLC, H2 2012 124
AndroScience Corporation, H2 2012 125
MolMed S.p.A., H2 2012 126
Mirna Therapeutics, Inc., H2 2012 127
Omeros Corporation, H2 2012 128
Taiwan Liposome Company, H2 2012 129
CureTech Ltd., H2 2012 130
Vicus Therapeutics, LLC, H2 2012 131
TRACON Pharmaceuticals, Inc., H2 2012 132
Regulus Therapeutics Inc., H2 2012 133
Galaxy Biotech, LLC, H2 2012 134
Therapure Biopharma Inc., H2 2012 135
VectorLogics, Inc., H2 2012 136
Polaris Group, H2 2012 137
Gradalis Inc., H2 2012 138
Assessment by Monotherapy Products, H2 2012 139
Assessment by Combination Products, H2 2012 140
Assessment by Stage and Route of Administration, H2 2012 143
Assessment by Stage and Molecule Type, H2 2012 146
Hepatocellular Carcinoma Therapeutics Drug Profile Updates 467
Hepatocellular Carcinoma Therapeutics Discontinued Products 546
Hepatocellular Carcinoma Therapeutics Discontinued Products (Contd..1) 547
Hepatocellular Carcinoma Therapeutics Dormant Products 548
Hepatocellular Carcinoma Therapeutics Dormant Products (Contd..1) 549
Hepatocellular Carcinoma Therapeutics Dormant Products (Contd..2) 550
Hepatocellular Carcinoma Therapeutics Dormant Products (Contd..3) 551
Hepatocellular Carcinoma Therapeutics Dormant Products (Contd..4) 552
Hepatocellular Carcinoma Therapeutics Dormant Products (Contd..5) 553
Hepatocellular Carcinoma Therapeutics Dormant Products (Contd..6) 554
Hepatocellular Carcinoma Therapeutics Dormant Products (Contd..7) 555
Hepatocellular Carcinoma Therapeutics Dormant Products (Contd..8) 556

List of Chart


Number of Products under Development for Hepatocellular Carcinoma, H2 2012 32
Products under Development for Hepatocellular Carcinoma Comparative Analysis, H2 2012 33
Products under Development by Companies, H2 2012 34
Products under Investigation by Universities/Institutes, H2 2012 41
Late Stage Products, H2 2012 49
Mid Clinical Stage Products, H2 2012 50
Early Clinical Stage Products, H2 2012 51
Discovery and Pre-Clinical Stage Products, H2 2012 52
Assessment by Monotherapy Products, H2 2012 139
Assessment by Combination Products, H2 2012 140
Assessment by Route of Administration, H2 2012 141
Assessment by Stage and Route of Administration, H2 2012 142
Assessment by Molecule Type, H2 2012 144
Assessment by Stage and Molecule Type, H2 2012 145

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *